Anticipating Advances in CAR T-Cell Therapies in Myeloma: Expert Discussion and Case Exploration

Register now for this 1.5-hour, CME-certified webinar to learn how the experts are using the latest data to guide CAR T-cell treatment for patients with relapsed/refractory multiple myeloma. Get up to date on patient eligibility for approved and investigational agents, outpatient vs inpatient administration, and managing acute and long-term toxicities.

To Register: On the Event Dates page, click a date/time and click the blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

• Welcome and Introduction
• Overview of CAR T-Cell Therapy
• CAR T-Cell Therapy for Multiple Myeloma
• Toxicity Management
• Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Faculty
Amrita Krishnan, MD

Director, Judy and Bernard Briskin Center for Multiple Myeloma Research
City of Hope
Duarte, California

Faculty
Nikhil Munshi, MD

Professor of Medicine, Harvard Medical School
Director of Basic and Correlative Science
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare professionals so they can confidently and competently integrate CAR T-cell therapy into their clinical practices.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify patients with multiple myeloma who are likely to benefit from CAR T-cell therapy or are eligible for clinical trial enrollment
  • Integrate into practice clinical trial data on CAR T-cell–based therapies for the treatment of patients with multiple myeloma
  • Manage toxicities associated with CAR T-cell therapy using available guidelines and online clinical resources and tools
  • Implement strategies to educate patients eligible for this treatment about the potential for these complications 

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.